Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavocept versus placebo with taxane plus cisplatin for advanced lung adenocarcinoma
2009-012983-14Phase 3Terminated
- Sponsor
- BioNumerik Pharmaceuticals
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Tavocept arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started Jul 2009; status: terminated.
02
Drugs
dimesna
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2009-012983-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012983-14.